#Canada #Montreal #CellCarta #Tempus AI #Oncology Diagnostics

Expanding Horizons in Oncology Diagnostics

In a significant step towards enhancing oncology diagnostics, CellCarta, a prominent contract research organization (CRO) in the biopharmaceutical sector, has partnered with Tempus AI, Inc. This collaboration marks Tempus as the second commercial laboratory to join CellCarta's CDx Commercialization Lab Network, further bolstering the network’s capabilities in providing comprehensive companion diagnostics to biopharmaceutical sponsors.

Understanding the Collaboration

Announced on August 6, 2026, this strategic partnership aims to streamline the pathway from companion diagnostic development to commercial utility in the U.S. oncology landscape. CellCarta has established itself as a leader in the field, focusing on the development and validation of companion diagnostics (CDx), regulatory submissions, and conducting centralized immunohistochemistry (IHC) and tissue-based testing.

Within the framework of the partnership, Tempus will facilitate test ordering for healthcare providers through its Tempus Hub, effectively routing sample tests to CellCarta and relaying results back to ordering clinicians. This streamlined process ensures that biopharmaceutical sponsors have a more expedited and direct route to not only develop companion diagnostics but also to make them readily accessible for clinical use.

Dr. Ehab A. El-Gabry, Chief Medical Officer at CellCarta, expressed that this collaboration significantly enhances the oncology aspect of their commercialization model. He noted, “Sponsors can develop and validate a companion diagnostic at CellCarta and leverage an established oncology diagnostics platform to ensure physician access and ordering.” This connection between regulatory execution and commercial launch strategies is vital for meeting the needs of both sponsors and patients.

The Significance of CellCarta’s CDx Accelerator Model

The CDx Commercialization Lab Network serves as an integral component of CellCarta’s CDx Accelerator Model, a structured framework that consists of four key stages: Build, Validate, Launch, and Transfer. This modularity allows biopharmaceutical sponsors to engage with CellCarta at different points in their program according to their individual needs. Whether it’s during the development phase or post-approval, CellCarta ensures continuity and consistency throughout the process.

As Tempus joins Sonic Healthcare USA as part of this network, it strengthens the oncology-focused offerings and adds specialized capabilities alongside Sonic's extensive reach in clinical and anatomic pathology. This partnership not only enhances the quality of companion diagnostic tests but also expands the potential for further partnerships and geographic reach in the future.

Real-World Implications

Christopher Ung, Chief Scientific Business Officer of CellCarta, emphasized the importance of integrating a central CDx strategy with a viable path to patient access. He remarked that adding Tempus to their network creates a robust entry point into U.S. oncology practice, providing biopharma sponsors with a tangible avenue for commercialization. This collaboration is set to alleviate a common barrier—ensuring that clinical diagnoses adjust swiftly to the realities of patient care.

This new partnership aims to fill a pivotal gap within many companion diagnostic programs, which often struggle to create the necessary commercial infrastructure for physicians to order tests. By connecting the capabilities of CellCarta in development and regulatory operations with commercial laboratory partners like Tempus, the initiative offers a comprehensive solution that extends beyond just the regulatory approval phase.

Future Outlook

CellCarta has outlined plans for further growth and development of its CDx Commercialization Lab Network. The organization aims to broaden its network's geographical reach, therapeutic scope, and commercial capabilities. By doing so, it hopes to provide sponsors with diverse pathways for launching centralized companion diagnostics, thus retaining flexibility for future expansions through additional laboratories or IVD kitted solutions.

For more information on CellCarta's diagnostic services and capabilities, interested parties can visit CellCarta's CDx Services.

Conclusion

Through this strategic partnership with Tempus, CellCarta is poised to transform the landscape of oncology diagnostics by creating a direct pathway for regulatory approval and commercial accessibility. This collaboration not only enhances their existing capabilities but also paves the way for innovative changes that could ultimately lead to improved patient outcomes in oncology care.